Recent research conducted by scientists at Cleveland institutions has revealed a novel enzyme, SCoR2, that plays a significant role in the body's fat production process. This discovery comes amid rising global rates of obesity and fatty liver disease, conditions that are increasingly linked to calorie-dense diets and sedentary lifestyles.
The study, published in the journal Science Signaling, demonstrates that SCoR2 is responsible for removing nitric oxide from proteins that regulate fat accumulation. The researchers found that when SCoR2 was inhibited, fat production was activated, leading to a cessation of weight gain and a reduction in harmful cholesterol levels in mouse models.
Jonathan Stamler, MD, who led the study, highlighted the enzyme's potential as a target for new therapeutic approaches. The team has initiated the development of a three-in-one drug aimed at addressing obesity, fatty liver disease, and heart disease. This drug, which is currently moving towards clinical testing, is anticipated to enter trials within the next 18 months.
Stamler explained that nitric oxide serves as a natural regulator of fat production. In various tissues, including the liver and fat tissue, it inhibits the proteins and genetic programs that contribute to fat and cholesterol synthesis.
The research is supported by the Harrington Discovery Institute, which focuses on translating scientific innovations into viable treatments for pressing medical issues. With an extensive portfolio of medicines under development, the institute aims to foster advancements that could significantly impact public health.
As the study progresses, further insights into SCoR2's role may open new avenues for combating obesity and related health concerns on a larger scale.